Cytosorbents Wins $1.5 Million Contract With US Army to Develop Medical Emergency Platform
12:00 PM EDT, 05/11/2021 (MT Newswires) -- Cytosorbents (CTSO) said Tuesday it has secured a contract valued at about $1.5 million for a period of 28 months from the US Army Medical Research and Development Command.
Under the contract, the company will help advance the development of the K+ontrol platform for the treatment of medical emergencies, such as severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.
The contract follows the completion of the previously announced phase 1 and phase 2 small business innovation research programs for the platform, which totaled about $1.15 million in previous funding.
Price: 7.79, Change: -0.12, Percent Change: -1.52